Autopsy report · NCT04194034

Study of Intrahepatic Arterial Infusion of TG6002 in Combination With 5-FC in Patients With Metastatic Colorectal Cancer

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“Study has been terminated after Phase I part on 23 February 2023”

The sponsor’s own words in the registry.

Life of this trial

Registered 1 month before it started.
Ran for about 3 years 1 month before it stopped.
15 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 1, Phase 2
Sponsor: Transgene
Sponsor type: Industry
Conditions: Colorectal Neoplasms
Interventions: TG6002; Flucytosine (5-FC)
Participants: 15
Sites: 3
Countries: France, United Kingdom

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.